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Abstract
Background: Solid tumors usually develop local hypoxia, which renders them resilient to radiotherapy. MiR-210 is
the most consistently and robustly induced miRNA under hypoxia and functions as a micro-controller of a wide
range of cellular responses to hypoxia. Hence, it is important to investigate the effect of knockdown of miR-210 in
tumorigenesis and evaluate the efficacy of knockdown of miR-210 in combination with radiotherapy on human
tumor xenograft in nude mice.
Materials and methods: SMMC-7721 Cells with stable integration of the anti-sense miR-210 were generated
through lentiviral-mediated gene transfer and were subcutaneously implanted into nude mice. Mice were
monitored for tumor growth and survival after radiotherapy. MiR-210 expression in tumor tissues was assessed by
real-time Reverse transcription-Polymerase Chain Reaction (RT-PCR). Protein expression of HIF-1α and miR-210
targeted genes in human hepatoma xenograft was assessed by Western blot. Tumors were analyzed for
proliferation, apoptosis, and angiogenesis biomarkers by immunohistochemistry staining.
Results: Tumor growth was delayed in miR-210 downregulated xenograft. Knockdown of miR-210 increased
protein expression of miR-210 targeted genes, but decreased HIF-1α protein in hepatoma xenograft. Knockdown of
miR-210 in combination with radiotherapy is more effective than radiotherapy alone or miR-210 knockdown
therapy alone in suppressing tumor growth and extending survival duration. Combined therapy decreased Ki-67
-positive cells and CD31-positive cells and increased TUNEL-positive cells in tumor xenograft.
Conclusions: Knockdown of miR-210 in combination with radiotherapy showed an enhanced anti-tumor effect on
human hepatoma xenograft. Our experiments demonstrated specific inhibition of miR-210 expression might be a
means to enhance the effectiveness of radiotherapy to human hepatoma.
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Background
Hepatocellular carcinoma (HCC) is the second leading
cause of cancer-related deaths worldwide [1]. There are
approximately 750,000 new cases of liver cancer, in
which 85-90% are HCC, reported globally per year and
most of the patients who develop HCC die of it [2]. The
treatment of patients with HCC is particularly challen-
ging because of high recurrence rate after surgical resec-
tion and resistance to chemotherapy and radiotherapy
[3]. As the current therapeutic options for HCC patients
are limited, there is an essential need to analyze the
molecular oncogenic mechanisms in order to determine
novel targets for specific systemic therapy.
HCC tumors, like many other human solid tumors,
usually develop local hypoxia, which promotes HCC
progression by facilitating angiogenesis and metabolic
adaptation and renders them resilient to radiotherapy
[4,5]. Adaptation of tumor cells to the hypoxic condi-
tions depends on the hypoxia-inducible factor 1 (HIF-1),
a transcriptional activator of cell survival, proliferation,
angiogenesis, invasion and metastasis genes [6,7]. Re-
cently, it has been demonstrated that a specific set of
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microRNAs (miRNAs) molecules are upregulated by hyp-
oxia [8]. MiRNAs are a class of small (21–22 nucleotide in
length) single-stranded noncoding RNAs, which partici-
pate in crucial biological processes, including development,
differentiation, apoptosis, metabolism and tumorigenesis
through inhibition of RNA translation or degradation of
target messenger RNA (mRNA) by base pairing between
their “seed region”, nucleotides 2–8, and their target genes’
3′ untranslated region (UTR) [9,10]. Among these hypoxia-
induced miRNAs, miR-210 is unique in its wide distribu-
tion, HIF dependence and robust upregulation in response
to hypoxia [11]. Several miR-210 targets which influence
cell proliferation, apoptosis, metabolism, and angiogenesis
have been identified such as E2F3, MYC antagonist (MNT),
caspase-8 associated protein-2 (CASP8AP2), iron-sulfur
cluster scaffold protein (ISCU) and the receptor tyrosine
kinase ligand ephrin-A3 (EFNA3) [12-16]. Thus, miR-210
functions as a micro-controller of a wide range of cellular
responses to hypoxia.
In preliminary studies we employed lentiviral-mediated
anti-sense miR-210 gene transfer technique to down-
regulate miR-210 expression in human hepatoma cells
and found that knockdown of miR-210 expression sig-
nificantly suppressed cell viability, induced cell arrest,
increased apoptotic rate and enhanced radiosensitivity
in hypoxia [17]. We hypothesis that miR-210 might
be a logical novel target to overcome hypoxia-induced
radioresistance and knock-down of miR-210 might
enhance radiosensitivity of hypoxic cells in hepatoma
xenograft through inhibiting proliferation and angio-
genesis and inducing apoptosis. In the present study,
we investigated the effect of knockdown of miR-210
in tumorigenesis and the efficacy of knockdown of
miR-210 in combination with radiotherapy in nude
mice bearing human hepatoma SMMC-7721 cells and
its mechanism.
Methods
Cell line and cell culture
The 293T and human hepatocarcinoma cell line SMMC-
7721 were purchased from the Type Culture Collection
of the Chinese Academy of Sciences and maintained in
Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 100 U/mL penicillin and
100 mg/mL streptomycin, in a 37°C incubator in a 5%
CO2 humidified atmosphere.
Generation of stable cell lines
SMMC-7721 Cells with stable integration of the anti-sense
miR-210 (5′-TCAGCCGCTGTCACACGCACAG-3′) or
scramble sequence (5′-TTCTCCGAACGTGTCACGTT
TC-3′) were generated through lentiviral-mediated gene
transfer [17]. To generate the respective viruses, 293T cells
were transfected with the lentiviral vector, pGLV-anti-210-
GFP or pGLV-scr-GFP, along with the packaging plasmid
PG-P1-VSVG, PG-P2-REV and PG-P3-RRE using calcium
phosphate following standard protocols. The target human
hepatocarcinoma SMMC-7721 cells were infected with
both of the viruses (encoding either anti-sense miR-210 or
scramble sequence) and selected using puromycin. Clonal
cell populations carrying anti-sense miR-210 or scramble
sequence were obtained by limiting dilution of 100–300
cells in three 96-well plates. After 4 weeks, single clones
were analyzed for positive GFP signals. The positive clones
were expanded for animal experiments.
Tumor-bearing mice model and treatment
For in vivo implantation, SMMC-7721, SMMC/Lv-scr and
SMMC/Lv-anti-210 cells were washed in Hanks’ balanced
salt solution (HBSS) and injected subcutaneously at 1 ×
106 cells in 0.1 ml HBSS in the right hind limb of 6–8-
week-old female Balb/c nude mice (Experimental Animals
Center of Shanghai Institute of Life Science, Shanghai,
China), respectively. When the diameter of tumor reached
about 6 ~ 8 mm, the mice implanted with SMMC-7721
cells (14 days after inoculation) were taken as control
and the mice implanted with SMMC/Lv-scr (14 days
after inoculation) or SMMC/Lv-anti-210 (21 days after
inoculation) cells were randomly divided. The mice im-
planted with SMMC/Lv-scr cells were divided into two
groups: The negative control vector group received no
X-irradiation; Radiotherapy group was subjected to 8 Gy
X-ray irradiation (6 MV, the dose rate was 100 cGy/min)
by a PRIMUS accelerator (SIEMENS Medical Solutions,
Erlangen, Germany) at room temperature. The mice im-
planted with SMMC/Lv-anti-210 cells were divided into
two groups: Anti-sense miR-210 therapy group received no
X-irradiation; Combined therapy group was subjected to 8
Gy X-ray irradiation. Irradiation was locally confined to
the tumors by shielding the rest of the body with lead and
was conducted 1 day after dividing. Mice were monitored
for tumor growth and survival. All the animal experi-
ments were conducted in accordance with Guidelines for
the Welfare of Animals in Experimental Neoplasia and
approved by Ethics Committee of Soochow University.
Real-time reverse transcription-polymerase chain reaction
(RT- PCR) analysis of miR-210 expression in tumor tissues
When the diameter of tumor reached about 6 ~ 8 mm,
three mice implanted with SMMC-7721 cells, SMMC/Lv-
scr and SMMC/Lv-anti-210 cells were killed and the
tumors were removed for real-time RT-PCR and Western
blot analysis, respectively. Total cellular RNA was iso-
lated from tumor tissue using Trizol reagent (Sangon
Inc. Shanghai, China) and transcribed using TaqMan
microRNA reverse transcription kit (Applied Biosystems)
according to the manufacturer’s protocol. MiR-210 ex-
pression was assessed by real-time PCR according to the
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TaqMan MicroRNA Assay protocol (Applied Biosystems).
The 20 μl reactions were incubated in a 96-well optical
plate at 95°C for 3 minutes, followed by 40 cycles of 95°C
for 12 seconds, and 58°C for 30 seconds. Fold changes in
miR-210 expression between treatments and controls were
determined by the 2-ΔΔCT method, normalizing the results
to U6 RNA expression level.
Western blot analysis of HIF-1α, MYC antagonist (MNT),
ephrin-A3 (EFNA3) and apoptosis-inducing factor,
mitochondrion-associated, 3 (AIFM3) protein expression
in tumor tissues
Tumor tissues were homogenized in 500 μl sodium
chloride-Tris buffer (pH 7.5) containing EDTA and pro-
tease inhibitors on ice for 30 s followed by 4 cycles of
freezing/thawing. Cell debris was removed by centrifuga-
tion at 10,000 g for 10 min at 4°C. Equal amounts of lysate
protein were fractionated by sodium dodecylsulfonate
(SDS)–polyacrylamide gel electrophoresis at 100 V for 80
min at room temperature. The separated proteins were
transferred to a nitrocellulose membrane, which was then
probed for 2 h at room temperature with rabbit mono-
clonal anti-HIF-1α, rabbit monoclonal anti-MNT, rabbit
monoclonal anti-EFNA3 and rabbit polyclonal anti-
AIFM3 (Santa Cruz Inc., Santa Cruz, CA, USA) and
rabbit polyclonal anti-β-actin (Sigma, St Louis, MO,
USA). Immune complexes were detected with horseradish
peroxidase-conjugated goat antibodies to rabbit immu-
noglobulin G (Amersham Biosciences, Little Chalfont,
England, UK). Immunoblots were visualized by chemilu-
minescence using a chemiluminescence kit (Invitrogen,
Carlsbad, CA, USA) and the specific bands were recorded
on X-ray film. Actin protein levels were used as a control
to verify equal protein loading.
Measurement of tumor volume
The tumor growth was monitored by measuring the
tumor diameters in two dimensions with a caliper
every second day. The tumor volumes were calculated
as follows: L(long diameter) × S2(short diameter)/2. The
formula for tumor inhibition rate is as follows: TIR(%) =
(1 − [experimental volume/control volume]) × 100.
Immunohistochemical studies for Ki-67 and cluster of
differentiation 31 (CD31) in tumor tissues
The mice used for immunohistochemical studies were
sacrificed 1 day after the irradiation. Tumor tissues were
fixed and imbedded in paraffin. Tumor sections of 5 μm
were cut from the embedded tissue and incubated with
specific primary antibodies, including rabbit monoclonal
antibody to human Ki-67 (KeyGen Biotech.) and rabbit
monoclonal antibody to mouse CD31 (eBioscience, Inc.,
San Diego, CA, USA) for 1 h at 37°C followed by over-
night at 4°C in humidity chamber. Negative controls
were incubated only with universal negative control anti-
bodies under identical conditions. The sections were
then incubated with appropriate biotinylated secondary
antibody for 60 min at room temperature. Thereafter,
sections were incubated with conjugated horseradish
peroxidase streptavidin (KeyGen Biotech.) for 60 min,
followed with 3,3'-diaminobenzidine (Sigma) working solu-
tion, and counterstained with hematoxylin. The prolifera-
tion index was determined as number of Ki-67-positive
(brown) cells/total number of cells × 100, and intratumoral
microvessel density (IMVD) was quantified by counting the
CD31-positive (brown) cells in 9 most highly vascularized
fields (400×) [18,19].
Detection of apoptotic cells in tumor tissues
Apoptotic cells in tumor tissues were detected by
terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP-biotin nick end labeling (TUNEL) stain, using
an In Situ Cell Death Detection Kit (KeyGen Biotech.)
following the manufacturer’s specifications. In brief,
tumor histological sections were permeabilized using a
mixture containing 0.1% sodium citrate and 0.1% Triton
X-100 and incubated with TUNEL reaction mixture
containing terminal deoxynucleotidyltransferase and
fluorescein-dUTP at 37°C for 60 min. The apoptotic
index was calculated as number of apoptotic (brown)
cells/total number of cells × 100 in 9 randomly selected
fields (400×).
Statistical analysis
Data are expressed as means ± standard deviations (SD)
for separate experiments. Statistical significance was esti-
mated by one-way analysis of variance (ANOVA) followed
by a post-hoc Least Significant Difference (LSD) test using
the SPSS version 12.0 software. The difference was consid-
ered statistically significant when p < 0.05.
Results
MiR-210 expression in hepatoma xenograft
MiR-210 expression in hepatoma xenograft was quantita-
tively measured using real-time RT-PCR. MiR-210 expres-
sion in SMMC-7721/Lv-anti-210 xenograft was significantly
decreased compared with that in SMMC/Lv-scr xenograft
(p < 0.001). In contrast, no obvious change of miR-210 ex-
pression was observed in SMMC-7721/Lv-scr xenograft
compared with that in SMMC-7721 xenograft (p > 0.05)
(Figure 1). These data demonstrate that stable integration of
anti-sense miR-210 significantly suppressed miR-210 expres-
sion in human hepatoma xenograft in nude mice.
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Effect of knockdown of miR-210 on protein expression of
HIF-1α and miR-210 targeted MNT, EFNA3 and AIFM3
genes in hepatoma xenograft
To investigate the mechanism underlying the knockdown
of miR-210 mediated growth delay in SMMC-7721/Lv-
anti-210 xenograft, we analyzed protein expression of HIF-
1α, MNT, EFNA3 and AIFM3 genes in human hepatoma
xenograft by Western blot. Experiments were repeated
three times. The relative levels of protein expression
were normalized against protein levels of an internal
control gene, β-actin, performed in the same run. The
level of MNT, EFNA3 and AIFM3 protein expression in
SMMC-7721/Lv-anti-210 xenograft was significantly
increased (p < 0.001), while the level of HIF-1α protein
expression was significantly decreased (p < 0.001), com-
pared with that in SMMC/Lv-scr xenograft. No obvious
change of these protein expression was observed in
SMMC-7721/Lv-scr xenograft compared with that in
SMMC-7721 xenograft (p > 0.05) (Figure 2). These re-
sults indicated that knockdown of miR-210 decreased
HIF-1α protein and increased protein expression of
miR-210 targeted MNT, EFNA3 and AIFM3 genes in
human hepatoma xenograft, which might lead to cell
proliferation and angiogenesis suppression and apop-
tosis enhancement.
Effect of knockdown of miR-210 in combination with
radiotherapy on human hepatoma xenograft growth in
athymic nude mice
The tumors were irradiated with 8 Gy one day after
dividing, followed by detection of hepatoma xenograft
growth (Figure 3). It can be seen that the tumor volume
was significantly decreased in mice of radiotherapy
group (from day 6 to 30, p < 0.001), anti-sense miR-210
therapy group (from day 6 to 30, p < 0.01 or p < 0.001) and
combined therapy group (from day 6 to 30, p < 0.001)
compared with control group. The tumor volume in
mice of negative control vector group showed no sig-
nificant change compared with control group (from day
3 to 30, p > 0.05). The average tumor volume reached
1772 mm3 in mice of control group on day 30, while only
593 mm3 (33.46% of control) in combined therapy group,
1295 mm3 (73.10% of control) in anti-sense miR-210
Figure 1 Real-time Reverse transcription-Polymerase Chain
Reaction (RT-PCR) analysis of miR-210 expression (fold change)
in human hepatoma xenograft. Error bars indicate the standard
error of the mean of three individual experiments. * indicates
p < 0.001 vs. SMMC/Lv-scr xenograft.
Figure 2 Detection of protein expression of HIF-1α and
miR-210 targeted genes in hepatoma xenograft by Western
blot. The relative levels of protein expression were normalized
against protein levels of an internal control gene, β-actin, performed
in the same run. (A) Western blot of HIF-1α, MNT, EFNA3 and AIFM3
protein. (B) Relative levels of HIF-1α, MNT, EFNA3 and AIFM3 protein
expression. Error bars indicate the standard error of the mean of three
individual experiments. * indicates p < 0.001 vs. SMMC/Lv-scr
xenograft.
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therapy group, and 913 mm3 (51.52% of control) in radio-
therapy group. In addition, the tumor volume was signifi-
cantly decreased in mice of combined therapy group
compared with anti-sense miR-210 therapy (from day 9 to
30, p < 0.01 or p < 0.001) or radiotherapy group (from day
12 to 30, p < 0.01 or p < 0.001).
Effect of knockdown of miR-210 in combination with
radiotherapy on survival of nude mice bearing human
hepatoma
The long-term outcome of knockdown of miR-210 in
combination with radiotherapy was evaluated by sur-
vival rates of mice bearing human hepatoma. Results of
survival were evaluated using Kaplan-Meier (Figure 4).
The median survival of control, negative control vector,
radiotherapy, anti-sense miR-210 therapy and combined
therapy group was 42.83 ± 4.75, 43.5 ± 6.06, 72.50 ± 5.58,
53.83 ± 6.85 and 84.33 ± 5.54 days, respectively. Survival
durations were significantly longer in radiotherapy group
(p < 0.001), anti-sense miR-210 therapy group (p < 0.001)
and combined therapy group (p < 0.001) compared with
control group. Survival durations were significantly longer
in combined therapy group compared with radiotherapy
(p < 0.01) or anti-sense miR-210 therapy group (p < 0.001).
Effect of knockdown of miR-210 in combination with
radiotherapy on cell proliferation in human hepatoma
xenograft
Effect of knockdown of miR-210 in combination with
radiotherapy on cell proliferation in human hepatoma
xenograft was examined by Ki-67 staining, which is a
specific marker of proliferating cell. In microscopic obser-
vation of tumors, lesser number of Ki-67-positive cells
was observed in radiotherapy group (p < 0.001), anti-sense
miR-210 therapy group (p < 0.01) and combined therapy
group (p < 0.001) compared with control group. The num-
ber of Ki-67-positive cells was significantly decreased in
combined therapy group compared with radiotherapy
group (p < 0.001) or anti-sense miR-210 therapy group
(p < 0.001) (Figure 5).
Effect of knockdown of miR-210 in combination with
radiotherapy on angiogenesis in human hepatoma
xenograft
Effect of knockdown of miR-210 in combination with
radiotherapy on tumor angiogenesis was analyzed by
CD31 staining, which is a specific marker of endothelial
cells. The pattern of staining was membranous and cyto-
plasmic. The microscopic examination revealed lower
IMVD in treatment groups of tumors. The quantifica-
tion of IMVD showed 9.11 ± 2.67, 9.89 ± 2.09, 8.22 ±
2.22, 4.89 ± 1.76 and 4.78 ± 1.79 in control, negative con-
trol vector, radiotherapy, anti-sense miR-210 therapy
and combined therapy group, respectively. IMVD was
Figure 3 Effect of knockdown of miR-210 in combination with
radiotherapy on human hepatoma xenograft growth. The tumor
volume of five groups with 6 animals in each group is shown. The
tumor volume was significantly decreased in mice of radiotherapy
group (from day 6 to 30), anti-sense miR-210 therapy group (from
day 6 to 30) and combined therapy group (from day 6 to 30)
compared with control group. In addition, the tumor volume was
significantly decreased in mice of combined therapy group
compared with anti-sense miR-210 therapy (from day 9 to 30) or
radiotherapy group (from day 12 to 30).
Figure 4 Effect of knockdown of miR-210 in combination with
radiotherapy on survival of mice bearing human hepatoma.
Results of survival were evaluated using Kaplan-Meier.
Yang et al. Radiation Oncology 2013, 8:102 Page 5 of 10
http://www.ro-journal.com/content/8/1/102
significantly decreased in anti-sense miR-210 therapy
group (p < 0.01) and combined therapy group (p < 0.01)
compared with control group (Figure 6).
Effect of knockdown of miR-210 in combination with
radiotherapy on apoptosis in human hepatoma xenograft
TUNEL staining was done to assess the apoptotic effect
of knockdown of miR-210 in combination with radio-
therapy in tumors, which showed an increased number
of TUNEL-positive cells in treatment groups compared
with control group. The quantification of TUNEL staining
showed 3.44 ± 1.42%, 3.89 ± 1.05%, 18.89 ± 4.28%, 10.89 ±
2.42% and 27.67 ± 3.87% positive cells in control, negative
control vector, radiotherapy, anti-sense miR-210 therapy
and combined therapy group, respectively. TUNEL-positive
cells was significantly increased in combined therapy group
compared with radiotherapy group (p < 0.001) or anti-sense
miR-210 therapy group (p < 0.001) (Figure 7).
Discussion
The stem–loop of miR-210 is located in an intron of a
noncoding RNA, which is transcribed from AK123483
on chromosome 11p15.5 [11]. MiR-210 is regulated by
HIF-1α, HIF-2α and nuclear factor κB (NFκB) [11,13,20].
HIF-1α directly binds to a hypoxia responsive element
(HRE) on the proximal miR-210 promoter, located 400 bp
upstream of the structure [11]. NFκB p50 can physically
interact with a conserved κB binding site and activate
miR-210 promoter under hypoxia [20].
MiR-210 expression is elevated in a variety of human
solid tumors [21,22]. The role of miR-210 in tumorigen-
esis has been investigated in several reports. However,
the results of these experiments are somewhat contro-
versial. It has been reported that high levels of miR-210
were associated with disease recurrence and short over-
all survival in head and neck squamous cell carcinoma
[23] and display an inverse correlation with disease-free
Figure 5 Effect of knockdown of miR-210 in combination with radiotherapy on cell proliferation in human hepatoma xenograft. Cell
proliferation in human hepatoma xenograft was examined by Ki-67 staining. (a) Ki-67 immunohistochemical staining of tumor sections. A: control
group; B: negative control vector group; C: radiotherapy group; D: anti-sense miR-210 therapy group; E: combined therapy group. The pictures
are at 400× magnification. (b) Percentage of Ki-67-positive cells in stained tumor sections. Error bars indicate the standard error of the mean
(SEM) (n = 9). * indicates p < 0.01, ** indicates p < 0.001 vs. control group; # indicates p < 0.001 vs. radiotherapy group; ^ indicates p < 0.001 vs.
anti-sense miR-210 therapy group.
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and overall patient survival in human breast cancer sam-
ples [24]. In addition, miR-210 levels correlate with breast
cancer aggressiveness and metastatic potential [25]. How-
ever, genomic deletions of miR-210 in human epithelial
ovarian cancer samples suggested these deletions as a pos-
sible trigger to tumorigenesis [12]. Huang et al. have dem-
onstrated that stably expression of miR-210 in implanted
tumor tissue could repress tumor growth in immunodefi-
cient mice [26]. Our preliminary findings suggested that
miR-210 might be a potential therapeutic target and
specific inhibition of miR-210 expression in combination
with radiotherapy showed an enhanced effect on hypoxic
human hepatoma cells in vitro [17]. In the present study,
in order to investigate the effect of knockdown of miR-210
in tumorigenesis in vivo, we subcutaneously implanted
miR-210 downregulated human hepatoma SMMC-7721
cells into nude mice. We found that tumor growth was sig-
nificantly delayed in SMMC-7721/Lv-anti-210 xenograft.
To investigate the mechanism underlying the knockdown
of miR-210 mediated tumor growth delay, we analyzed
protein expression of HIF-1α gene and miR-210 targeted
MNT, EFNA3 and AIFM3 genes in human hepatoma
xenograft by Western blot. MNT represses Myc target
genes by binding the E box DNA sequence (CANNTG)
after forming heterodimers with Max [27,28]. MiR-210
could override hypoxia-induced cell cycle arrest by
downregulating MNT [13]. EFNA3 is an ephrin family
member involving vascular development [29]. Over-
expression of EFNA3 significantly blocked the angiogen-
esis effect of miR-210 [30]. AIFM3, a gene homologous to
the apoptosis-inducing factor (AIF), is a direct target of
miR-210 in human hepatoma cells [17,31]. AIFM3 in-
creases cytochrome c release and induces apoptosis in a
caspase-dependent manner [32]. Our preliminary studies
showed that AIFM3 downregulation by siRNA attenuated
radiation induced apoptosis in miR-210 downregulated
hypoxic human hepatoma cells, which suggest miR-210
downregulation mediate enhanced radiation induced
apoptosis in hypoxic human hepatoma cells through
AIFM3 gene at least in part [17]. The Western blot results
Figure 6 Effect of knockdown of miR-210 in combination with radiotherapy on angiogenesis in human hepatoma xenograft. Tumor
angiogenesis was analyzed by CD31 staining. (a) CD31 immunohistochemical staining of tumor sections. A: control group; B: negative control
vector group; C: radiotherapy group; D: anti-sense miR-210 therapy group; E: combined therapy group. The pictures are at 400× magnification.
(b) IMVD in stained tumor sections. Error bars indicate SEM (n = 9). * indicates p < 0.01 vs. control group.
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indicated that knockdown of miR-210 decreased HIF-1α
protein and increased protein expression of MNT, EFNA3
and AIFM3 genes in human hepatoma xenograft. HIF-1α
protein downregulation by knockdown of miR-210 might
be due to destruction of a hypoxia-induced positive feed-
back loop, in which HIF-1α induce miR-210 expression in
hypoxia, which represses glycerol-3-phosphate dehydro-
genase 1-like (GPD1L), contributing to increase of HIF-1α
protein stability [33]. HIF-1α downregulation may inhibit
proliferation, induce apoptosis, and enhance radiosensitiv-
ity in hypoxic cancer cells [4,5]. In immunohistochemical
studies anti-sense miR-210 therapy group showed de-
creased Ki-67-positive cells and IMVD and increased
TUNEL-positive cells compared with control and negative
control vector group. These results suggest that knock-
down of miR-210 may lead to tumor growth delay by cell
proliferation and angiogenesis suppression and apoptosis
enhancement.
In order to investigate the efficacy of knockdown of
miR-210 in combination with radiotherapy in nude
mice bearing human hepatoma SMMC-7721 cells, mice
were monitored for tumor growth and survival after
treatment as described in Materials and Methods. Results
showed that the average tumor volume in combined
therapy group reached 593 mm3 on day 30, only
33.46% of control group. In addition, survival durations
were significantly longer in combined therapy group
compared with control, radiotherapy or anti-sense miR-
210 therapy group. These results suggest that knock-
down of miR-210 in combination with radiotherapy is
more effective than radiotherapy alone or anti-sense
miR-210 therapy alone in suppressing tumor growth
and extending survival duration. Analyzing associated
mechanisms of the in vivo efficacy of combined therapy,
we observed its inhibitory effects on cell proliferation
(by Ki-67 staining) and tumor angiogenesis (by CD31
Figure 7 Effect of knockdown of miR-210 in combination with radiotherapy on apoptosis in human hepatoma xenograft. Apoptosis in
tumors was analyzed by TUNEL staining. (a) TUNEL staining of tumor sections. A: control group; B: negative control vector group; C: radiotherapy
group; D: anti-sense miR-210 therapy group; E: combined therapy group. The pictures are at 400× magnification. (b) Percentage of
TUNEL-positive cells in stained tumor sections. Error bars indicate SEM (n = 9). * indicates p < 0.001 vs. control group; # indicates p < 0.001 vs.
radiotherapy group; ^ indicates p < 0.001 vs. anti-sense miR-210 therapy group.
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staining) and an enhancing effect on apoptosis (by
TUNEL staining) in human hepatoma xenograft.
Conclusions
In summary, our studies demonstrated that knockdown of
miR-210 inhibited proliferation and angiogenesis, induced
apoptosis in human hepatoma SMMC-7721 xenograft and
knockdown of miR-210 in combination with radiotherapy
showed an enhanced anti-tumor effect on human hepa-
toma. These findings suggest that specific inhibition of
miR-210 expression may be a means to enhance the effect-
iveness of radiotherapy to human hepatoma.
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